Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant

PURPOSE: To assess short-term functional and anatomical outcomes of refractory diabetic macular edema (DME) following a switch from ranibizumab or dexamethasone to aflibercept. METHODS: We included retrospectively eyes with persistent DME after at least 3 ranibizumab and/or one dexamethasone implant...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbaut, Antoine, Fajnkuchen, Franck, Qu-Knafo, Lise, Nghiem-Buffet, Sylvia, Bodaghi, Bahram, Giocanti-Auregan, Audrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576400/
https://www.ncbi.nlm.nih.gov/pubmed/28900543
http://dx.doi.org/10.1155/2017/8035013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576400/
https://www.ncbi.nlm.nih.gov/pubmed/28900543
http://dx.doi.org/10.1155/2017/8035013

Ejemplares similares